PHP
Parkman Healthcare Partners Portfolio holdings
AUM
$864M
This Quarter Return
+3.03%
1 Year Return
+33.7%
3 Year Return
+258.24%
5 Year Return
+878.92%
10 Year Return
–
AUM
$751M
AUM Growth
+$751M
(-4.2%)
Cap. Flow
+$3.19M
Cap. Flow
% of AUM
0.42%
Top 10 Holdings %
Top 10 Hldgs %
35.59%
Holding
104
New
11
Increased
46
Reduced
31
Closed
15
Top Buys
| 1 |
Gilead Sciences
GILD
|
$22.7M |
| 2 |
Stryker
SYK
|
$17.9M |
| 3 |
McKesson
MCK
|
$13.1M |
| 4 |
Viridian Therapeutics
VRDN
|
$12.7M |
| 5 |
Edwards Lifesciences
EW
|
$10.8M |
Top Sells
| 1 |
Teleflex
TFX
|
$23.8M |
| 2 |
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
$16.4M |
| 3 |
Agios Pharmaceuticals
AGIO
|
$12.7M |
| 4 |
Boston Scientific
BSX
|
$9.81M |
| 5 |
Eli Lilly
LLY
|
$9.43M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Gilead Sciences
GILD
$140B
| $34.6M | 4.61% | 374,825 +245,800 | +191% | +$22.7M |
|
|
VRNA
2
Verona Pharma
VRNA
$9.16B
| $33.5M | 4.46% | 720,657 +94,205 | +15% | +$4.37M |
|
3
Insulet
PODD
$23.9B
| $32.8M | 4.37% | 125,761 -33,928 | -21% | -$8.86M |
|
|
4
Boston Scientific
BSX
$156B
| $30.1M | 4.01% | 337,354 -109,842 | -25% | -$9.81M |
|
|
5
Stryker
SYK
$150B
| $28M | 3.73% | 77,717 +49,717 | +178% | +$17.9M |
|
6
Cooper Companies
COO
$13.4B
| $25.2M | 3.36% | 274,569 -18,024 | -6% | -$1.66M |
|
|
7
Eli Lilly
LLY
$657B
| $21.7M | 2.9% | 28,163 -12,221 | -30% | -$9.43M |
|
|
8
Viridian Therapeutics
VRDN
$1.5B
| $20.8M | 2.78% | 1,087,634 +662,634 | +156% | +$12.7M |
|
|
ITCI
9
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $20.3M | 2.7% | 243,123 +1,548 | +0.6% | +$129K |
|
10
MannKind Corp
MNKD
$1.41B
| $20.1M | 2.68% | 3,126,727 -177,358 | -5% | -$1.14M |
|
11
Abbott
ABT
$231B
| $20M | 2.67% | 176,994 +53,393 | +43% | +$6.04M |
|
12
Travere Therapeutics
TVTX
$1.56B
| $19.5M | 2.59% | 1,117,792 +31,725 | +3% | +$553K |
|
13
Arcus Biosciences
RCUS
$1.13B
| $19M | 2.53% | 1,273,789 +248,035 | +24% | +$3.69M |
|
14
Becton Dickinson
BDX
$55.3B
| $16M | 2.13% | 70,404 +10,393 | +17% | +$2.36M |
|
15
Neurocrine Biosciences
NBIX
$13.8B
| $15.8M | 2.1% | 115,727 -14,113 | -11% | -$1.93M |
|
16
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $15.1M | 2.02% | 765,453 +10,209 | +1% | +$202K |
|
17
Quest Diagnostics
DGX
$20.3B
| $13.6M | 1.82% | 90,352 +35,352 | +64% | +$5.33M |
|
18
Tenet Healthcare
THC
$16.3B
| $13.5M | 1.8% | 106,987 +13,234 | +14% | +$1.67M |
|
19
United Therapeutics
UTHR
$13.8B
| $13.2M | 1.76% | 37,472 -26,559 | -41% | -$9.37M |
|
|
20
McKesson
MCK
$85.4B
| $13.1M | 1.75% | +23,000 | New | +$13.1M |
|
21
Day One Biopharmaceuticals
DAWN
$769M
| $12.7M | 1.69% | 1,000,474 +76,334 | +8% | +$967K |
|
22
Qiagen
QGEN
$10.1B
| $12.3M | 1.64% | 277,272 +66,503 | +32% | +$2.96M |
|
23
CVRx
CVRX
$205M
| $11.7M | 1.55% | 921,174 +238,277 | +35% | +$3.02M |
|
24
Schrodinger
SDGR
$1.44B
| $10.9M | 1.45% | 563,091 +3,986 | +0.7% | +$76.9K |
|
|
25
Edwards Lifesciences
EW
$47.8B
| $10.8M | 1.43% | +145,214 | New | +$10.8M |
|